What we are studying
Medical scientists have found that most cells in your body turn over rapidly, but with age some cells become inflamed. This means the cells no longer turn over and can become destructive to nearby cells, creating more inflamed cells and releasing signals that can increase inflammation in the rest of the body. Patients with IPF have even greater numbers of inflamed cells than other older people, but researchers are not sure how this affects their disease.
Investigationers have found ways to eliminate the cells in the body that have become inflamed and destructive; the most effective way to target these cells in animals is to use a combination therapy of dasatinib and quercetin. Dasatinib is a chemotherapy drug currently used to treat leukemia. Dasatinib has been approved by the US Food and Drug Administration (FDA), but it has not been approved for use in IPF or for use to reduce the number of inflamed cells. Quercetin is a flavonoid found in black currants, cilantro, red onion, watercress, cranberries and other fruits and herbs, and is generally recognized as safe by the Food and Drug Administration (FDA).
In animal models of IPF and aging, dasatinib and quercetin can reduce the number of inflamed cells and improve endurance, but the combination treatment has never been studied in people. The purpose of this research study is to test the safety of dasatinib and quercetin and see what effects (good and bad) it has on you, the number of inflamed cells you have and your IPF.
You will be paid $150 if you complete all the scheduled study visits. If you withdraw for any reason from the study before completion you will be paid $75 for each complete study visit (baseline and follow-up).